The bipartisan PREVENT Pandemics Act, which seeks to put into U.S. law many of the lessons learned from the COVID-19 pandemic, marked its first milestone March 15, with the Senate Health, Education, Labor and Pensions (HELP) Committee sending it to the full Senate with a do-pass recommendation on a 20-2 vote.
The Gates Foundation is joining with other philanthropic funders in launching an initiative to develop small-molecule antiviral drugs to lay in as part of preparations for the next pandemic.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Almirall, Ascletis, Biogen, Biomed, Eisai, Enochian, Eyenovia, Gain, Iaso, Imugene, Innovation, Krystal, Merck, Ovid, Passage, Periphagen, Scripps Research, University of Michigan.
Chinese state-owned enterprise China Meheco Group Co. Ltd. has signed a deal with Pfizer Inc. to be its mainland China partner for the commercialization of the COVID-19 pill Paxlovid (nirmatrelvir and ritonavir), which won conditional approval from China’s NMPA earlier this year.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Beigene, Hoth, Immunome, Oncternal, Orion, SGC Cell Therapy, Valneva.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Audere, Medical Diagnostech, Nexstim, Royal Philips.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allogene, Antengene, Atyr, Immutep, In3bio, Intellia, Pharmazz, Quoin, Samsung Bioepis, Selecta, Servier, TG, Tracon.